|
ID. | Gender | GA (w) | BW (kg) | Eyes | Zoneа | Stage | Plusβ | Range (hr) | Time of the first treatment (week) | Medicineβ | Reasons for treatmentγ |
|
1 | Male | 26.6 | 0.95 | OD | II | 2 | ± | 7 | 42.2 | C | Preplus |
OS | II | 2 | ± | 7 | 42.2 | C | Preplus |
2 | Male | 27.6 | 1.00 | OD | II | 2 | ± | 6 | 43.6 | C | Follow-up time ≥44 w, ridge aggravation, preplus |
OS | II | 2 | ± | 6 | 43.6 | C | Follow-up time ≥44 w, preplus |
3 | Male | 30.0 | 1.30 | OD | II | 3 | ± | 6 | 41.3 | C | Ridge aggravation, preplus |
OS | II | 2 | − | 6 | 42.3 | C | Ridge aggravation, contralateral eye |
4 | Female | 29.0 | 0.90 | OD | II | 2 | − | 5 | 45.7 | C | Follow-up time ≥44 w, logistical considerations |
OS | II | 2 | - | 5 | 46.7 | C | Follow-up time ≥44 w, logistical considerations |
5 | Male | 28.7 | 1.30 | OD | I | 1 | ± | 12 | 34.0 | C | Preplus, logistical considerations |
OS | I | 1 | ± | 12 | 34.0 | C | Preplus, logistical considerations |
6 | Female | 30.0 | 1.66 | OD | II | 2 | ± | 5 | 38.0 | R | Preplus |
OS | II | 3 | ± | 5 | 39.0 | R | Preplus |
7 | Female | 27.6 | 1.10 | OD | II | 3 | ± | 12 | 38.6 | R | Ridge aggravation, preplus |
OS | II | 3 | ± | 12 | 38.6 | R | Ridge aggravation, preplus |
8 | Female | 27.0 | 0.98 | OD | II | 2 | ± | 5 | 36.3 | C | Preplus |
OS | II | 2 | ± | 5 | 37.3 | C | Preplus |
9 | Male | 29.4 | 1.10 | OD | II | 2 | ± | 6 | 40.7 | R | Preplus |
OS | II | 2 | ± | 6 | 40.7 | R | Preplus |
10 | Male | 32.0 | 1.50 | OD | II | 3 | − | 6 | 40.9 | R | Type 1 |
OS | II | 3 | ± | 6 | 40.9 | R | Ridge aggravation, preplus, contralateral eye |
11 | Male | 30.7 | 1.66 | OD | II | 2 | ± | 5 | 35.6 | C | Preplus |
OS | II | 2 | ± | 7 | 35.6 | C | Preplus |
12 | Male | 30.0 | 1.63 | OD | II | 3 | − | 5 | 38.4 | A | Type 1 |
OS | II | 3 | ± | 5 | 38.4 | A | Ridge aggravation, preplus, contralateral eye |
13 | Male | 26.9 | 0.72 | OD | II | 3 | ± | 12 | 37.6 | C | Preplus |
OS | II | 2 | − | 12 | NA | NA | Untreated |
14 | Female | 28.4 | 1.05 | OD | II | 3 | − | 5 | 44.7 | C | Follow-up time ≥44 w, ridge aggravation |
OS | II | 3 | − | 5 | 44.7 | C | Follow-up time ≥44 w, ridge aggravation |
15 | Female | 28.9 | 1.13 | OD | Posterior II | 2 | − | 12 | 39.8 | C | Contralateral eye |
OS | Posterior II | 2 | + | 12 | 39.8 | C | Type 1 |
16 | Female | 27.0 | 0.73 | OD | III | 2 | − | 3 | NA | NA | Untreated |
OS | II | 3 | ± | 4 | 39.7 | C | Ridge aggravation, preplus |
17 | Female | 26.7 | 0.71 | OD | II | 2 | ± | 6 | 39.8 | C | Preplus |
OS | II | 2 | ± | 6 | 39.8 | C | Preplus |
18 | Male | 27.3 | 1.10 | OD | II | 2 | ± | 10 | 37.7 | C | Preplus |
OS | II | 2 | ± | 10 | 37.7 | C | Preplus |
19 | Female | 25.6 | 0.90 | OD | II | 2 | − | 3 | NA | NA | Untreated |
OS | II | 3 | ± | 3 | 39.6 | C | Ridge aggravation, preplus |
20 | Male | 26.7 | 0.85 | OD | II | 3 | ± | 7 | 43.3 | C | Ridge aggravation, preplus |
OS | II | 2 | − | 6 | NA | NA | Untreated |
21 | Female | 25.9 | 0.86 | OD | Posterior II | 2 | ± | 10 | 38.0 | C | Preplus |
OS | Posterior II | 2 | ± | 10 | 38.0 | C | Preplus |
22 | Male | 26.9 | 0.68 | OD | II | 2 | ± | 12 | 37.2 | A | Preplus |
OS | II | 2 | ± | 12 | 37.2 | A | Preplus |
23 | Male | 27.6 | 1.10 | OD | Posterior II | 3 | ± | 12 | 36.6 | A | Preplus |
OS | Posterior II | 3 | ± | 12 | 36.6 | A | Preplus |
24 | Male | 28.0 | 1.17 | OD | II | 2 | ± | 10 | 37.1 | C | Preplus |
OS | II | 2 | ± | 10 | 37.1 | C | Preplus |
25 | Male | 31.0 | 1.75 | OD | II | 3 | ± | 5 | 38.9 | A | Ridge aggravation, preplus |
OS | II | 2 | − | 5 | 38.9 | A | Contralateral eye |
26 | Female | 27.9 | 1.13 | OD | II | 2 | ± | 5 | 40.5 | C | Preplus |
OS | II | 2 | ± | 5 | 40.5 | C | Preplus |
27 | Female | 29.4 | 1.00 | OD | II | 2 | ± | 6 | 43.4 | C | Preplus |
OS | II | 2 | − | 5 | NA | NA | Untreated |
28 | Female | 27.0 | 1.10 | OD | II | 3 | ± | 5 | 42.6 | C | Ridge aggravation, preplus |
OS | II | 3 | ± | 5 | 42.6 | C | Ridge aggravation, preplus |
29 | Female | 27.3 | 1.08 | OD | II | 2 | ± | 5 | 37.7 | C | Preplus |
OS | II | 2 | ± | 5 | 37.7 | C | Preplus |
30 | Male | 28.4 | 1.19 | OD | II | 2 | − | 4 | NA | NA | Untreated |
OS | II | 3 | ± | 4 | 43.8 | C | Preplus |
31 | Male | 26.7 | 0.75 | OD | II | 2 | ± | 10 | 40.8 | C | Preplus |
OS | II | 2 | ± | 10 | 40.8 | C | Preplus |
32 | Female | 29.7 | 1.25 | OD | II | 3 | ± | 6 | 40.0 | C | Ridge aggravation, preplus |
OS | II | 3 | ± | 6 | 40.0 | C | Ridge aggravation, preplus |
33 | Female | 33.1 | 1.80 | OD | II | 2 | ± | 5 | 44.8 | C | Ridge aggravation, preplus, follow-up time ≥44 w |
OS | II | 3 | ± | 6 | 44.8 | C | Ridge aggravation, preplus, follow-up time ≥44 w |
34 | Male | 27.9 | 0.97 | OD | II | 2 | + | 12 | 36.9 | R | Type 1 |
OS | II | 2 | ± | 12 | 36.9 | R | Preplus, contralateral eye |
35 | Female | 27.9 | 1.18 | OD | II | 2 | − | 3 | NA | NA | Untreated |
OS | II | 3 | ± | 3 | 39.8 | C | Ridge aggravation, preplus |
36 | Male | 31.9 | 2.28 | OD | II | 2 | ± | 6 | 39.0 | A | Contralateral eye, preplus |
OS | II | 3 | ± | 6 | 39.0 | A | Ridge aggravation, preplus |
37 | Male | 25.6 | 0.74 | OD | II | 2 | ± | 12 | 39.0 | C | Preplus |
OS | II | 2 | ± | 12 | 39.0 | C | Preplus |
38 | Male | 30.6 | 1.50 | OD | II | 2 | ± | 6 | 37.7 | A | Preplus, contralateral eye |
OS | II | 2 | + | 6 | 37.7 | A | Type 1 |
39 | Female | 29.0 | 1.26 | OD | II | 3 | + | 5 | 40.9 | C | Type 1 |
OS | II | 2 | ± | 6 | 40.9 | C | Ridge aggravation, preplus, contralateral eye |
|